Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of symptoms Related to Chronic Inflammation. Brian M. Mehling, Louis Quartararo, Marine Manvelyan, Paul Wang, Dong-Cheng Wu   Full Link [...]

CellR4 2015; 3 (2): e1562 Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation – Before Author’s Corrections Mehling B. M. , Quartararo L. , Manvelyan M. , Wang P. [...]

Brian M. Mehling1, Louis Quartararo1, Marine Manvelyan*1, Paul Wang1 and Dong-Cheng Wu2,3 1Blue Horizon International, LLC, 214 State Street, Hackensack, New Jersey 07601, USA 2Biochemistry Institute, Wuhan University, Hubei 430071, P.R. China 3Department of Stem Cells, Wuhan Hongqiao Brain Hospital, [...]

CellR4 2018; 6 (2): e2521 Allogeneic umbilical cord blood mononuclear cell therapy for spinal cord injury – a retrospective cohort study Mehling B. M. , Wu D. C. , Quartararo L. , Roman S. J. , Pickoff A. S. , [...]

J Clin Med Res. 2020 Nov; 12(11): 747–751. Published online 2020 Nov 3. doi: 10.14740/jocmr4354 PMCID: PMC7665865 PMID: 33224377 A Retrospective Study of Stromal Vascular Fraction Cell Therapy for Osteoarthritis Brian Mehling,a Milan Hric,b Adriana Salatkova,b Robert Vetrak,b Doreen Santora,a Miriama [...]

Safety study of cultured human Wharton’s Jelly mesenchymal stem cell therapy for multiple indications – a retrospective descriptive study Mehling B. M. , Wu D. C. , Santora D. , O’Gorman E. , Novakova K. , Spencer G. , Thomas [...]